β-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells

Cancer Research

Volumn 63, Issue 24, 2003, Pages 9023-9031

  Hong, Feng ^a,b,d   Hansen, Richard D ^a   Yan, Jun ^a,b   Allendorf, Daniel J ^b   Baran, Jarek T ^a   Ostroff, Gary R ^c,e   Ross, Gordon D ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c Biopolymer Engineering Inc   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e GlucaDel Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BETA 1,3 GLUCAN; BETA GLUCAN; BETA-1,3-GLUCAN; CANCER ANTIBODY; CD11B ANTIGEN; CETUXIMAB; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; GANGLIOSIDE GD2; GLUCAN; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; MUCIN 1; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; BREAST TUMOR; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; GRANULOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; KILLER CELL; LIVER TUMOR; METABOLISM; METHODOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; SURVIVAL RATE; TARGET CELL DESTRUCTION; TUMOR ESCAPE; TUMOR REGRESSION;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; BETA-GLUCANS; COMPLEMENT C3; COMPLEMENT C3B; GLUCANS; GRANULOCYTES; IMMUNOTHERAPY; MACROPHAGE-1 ANTIGEN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 0346690258     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Wang, S. C., Zhang, L., Hortobagyi, G. N., and Hung, M. C. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol., 28: 21-29, 2001.
2. Leyland-Jones, B. Trastuzumab: hopes and realities. Lancet Oncol., 3: 137-144, 2002.
3. Ranson, M., and Sliwkowski, M. X. Perspectives on anti-HER monoclonal antibodies. Oncology, 63 (Suppl. 1): 17-24, 2002.
4. Johnson, P., and Glennie, M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol., 30: 3-8, 2003.
5. Plosker, G. L., and Figgitt, D. P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 63: 803-843, 2003.
6. Ross, J. S., Gray, K., Gray, G. S., Worland, P. J., and Rolfe, M. Anticancer antibodies. Am. J. Clin. Pathol., 119: 472-485, 2003.
7. Herbst, R. S., and Langer, C. J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol., 29: 27-36, 2002.
8. Mendelsohn, J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol., 20: 1S-13S, 2002.
9. Li, L., Spendlove, I., Morgan, J., and Durrant, L. G. CD55 is over-expressed in the tumour environment. Br. J. Cancer, 84: 80-86, 2001.
10. Vetvicka, V., Thornton, B. P., and Ross, G. D. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or NK cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Investig., 98: 50-61, 1996.
11. Vetvicka, V., Thornton, B. P., Wieman, T. J., and Ross, G. D. Targeting of NK cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159: 599-605, 1997.
12. 2-integrin glycoprotein. Crit. Rev. Immunol., 20: 197-222, 2000.
13. Tanabe, H., Imai, N., and Takechi, K. Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer. J. Jpn. Soc. Cancer Ther., 25: 1657-1667, 1990.
14. Takeshita, K., Saito, N., Sato, Y., Maruyama, M., Sunagawa, M., Habu, H., and Endo, M. Diversity of complement activation by lentinan, an antitumor polysaccharide, in gastric cancer patients. Nippon Geka Gakkai Zasshi, 92: 5-11, 1991.
15. Toi, M., Hattori, T., Akagi, M., Inokuchi, K., Orita, K., Sugimachi, K., Dohi, K., Nomura, Y., Monden, Y., and Hamada, Y. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer (Phila.), 70: 2475-2483, 1992.
16. Kimura, Y., Tojima, H., Fukase, S., and Takeda, K. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. 511 (Suppl.): 192-195, 1994.
17. Tari, K., Satake, I., Nakagomi, K., Ozawa, K., Oowada, F., Higashi, Y., Negishi, T., Yamada, T., Saito, H., and Yoshida, K. Effect of lentinan for advanced prostate carcinoma. Acta Urol. Jpn., 40: 119-123, 1994.
18. Matsuoka, H., Seo, Y., Wakasugi, H., Saito, T., and Tomoda, H. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res., 17: 2751-2755, 1997.
19. Xia, Y., and Ross, G. D. Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol., 162: 7285-7293, 1999.
20. Xia, Y., Vetvicka, V., Yan, J., Hanikyrova, M., Mayadas, T. N., and Ross, G. D. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol., 162: 2281-2290, 1999.
21. Wessels, M. R., Butko, P., Ma, M. H., Warren, H. B., Lage, A. L., and Carroll, M. C. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA, 92: 11490-11494, 1995.
22. Coxon, A., Rieu, P., Barkalow, F. J., Askari, S., Sharpe, A. H., Von Andrian, U. H., Arnaout, M. A., and Mayadas, T. N. A novel role for the β2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity, 5: 653-666, 1996.
23. Prodeus, A. P., Zhou, X. N., Maurer, M., Galli, S. J., and Carroll, M. C. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (Lond.), 390: 172-175, 1997.
24. Tang, T., Rosenkranz, A., Assmann, K. J., Goodman, M. J., Gutierrez-Ramos, J. C., Carroll, M. C., Cotran, R. S., and Mayadas, T. N. A role for Mac-1 (CD11b/CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcγ receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J. Exp. Med., 186: 1853-1863, 1997.
25. Soriano, S. G., Coxon, A., Wang, Y. F., Frosch, M. P., Lipton, S. A., Hickey, P. R., Mayadas, T. N., and Chan, P. H. Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke, 30: 134-139, 1999.
26. Yan, J., Vetvicka, V., Xia, Y., Coxon, A., Carroll, M. C., Mayadas, T. N., and Ross, G. D. β-Glucan, a "specific" biologic response modifier that uses antibodies to target tumors for recognition by complement receptor type 3 (CD11b/CD18). J. Immunol., 163: 3045-3052, 1999.
27. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. Antitumor effect of locally produced CD95 ligand. Nat. Med., 3: 165-170, 1997.
28. Elsasser, D., Stadick, H., Stark, S., van de Winkel, J. G., Gramatzki, M., Schrott, K. M., Valerius, T., and Schafhauser, W. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Anticancer Res., 19: 1525-1528, 1999.
29. van Spriel, A. B., Van Ojik, H. H., Bakker, A., Jansen, M. J., and van de Winkel, J. G. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood, 101: 253-258, 2003.
30. Raychaudhuri, S., Saeki, Y., Fuji, H., and Kohler, H. Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J. Immunol., 137: 1743-1749, 1986.
31. Hank, J. A., Robinson, R. R., Surfus, J., Mueller, B. M., Reisfeld, R. A, Cheung, N-K. V., and Sondel, P. M. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res., 50: 5234-5239, 1990.
32. Uttenreuther-Fischer, M. M., Huang, C. S., Reisfeld, R. A., and Yu, A. L. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a Phase I trial in pediatric cancer patients. Cancer Immunol. Immunother., 41: 29-36, 1995.
33. Xing, P. X., Prenzoska, J., Quelch, K., and McKenzie, I. F. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res., 52: 2310-2317, 1992.
34. Hestdal, K., Ruscetti, F. W., Ihle, J. N., Jacobsen, S. E., Dubois, C. M., Kopp, W. C., Longo, D. L., and Keller, J. R. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol., 147: 22-28, 1991.
35. Aida, Y., and Pabst, M. J. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. Methods. 132: 191-195, 1990.
36. Thornton, B. P., Vetvicka, V., Pitman, M., Goldman, R. C., and Ross, G. D. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol., 156: 1235-1246, 1996.
37. Soares, M. M., Mehta, V., and Finn, O. J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol., 166: 6555-6563, 2001.
38. Wipke, B. T., and Allen, P. M. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol., 167: 1601-1608, 2001.
39. Cheung, N. K., and Modak, S. Oral (1→3), (1→4)-β-D-glucan synergizes with anfiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res., 8: 1217-1223, 2002.
40. Spiridon, C. I., Ghetie, M. A., Uhr, J., Marches, R., Li, J. L., Shen, G. L., and Vitetta, E. S. Targeting multiple her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res., 8: 1720-1730, 2002.
41. Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., and Mulkerrin, M. G. Mapping of the Clq binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol., 164: 4178-4184, 2000.
42. Cragg, M. S., Morgan, S. M., Chan, H. T., Morgan, B. P., Filatov, A. V., Johnson, P. W., French, R. R., and Glennie, M. J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood, 101: 1045-1052, 2003.
43. Herbst, R. S., and Hong, W. K. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin. Oncol., 29: 18-30, 2002.
44. Brown, G. D., Taylor, P. R., Reid, D. M., Willment, J. A., Williams, D. L., Martinez-Pomares, L., Wong, S. Y., and Gordon, S. Dectin-1 is a major β-glucan receptor on macrophages. J. Exp. Med., 196: 407-412, 2002.
45. Taylor, P. R., Brown, G. D., Reid, D. M., Willment, J. A., Martinez-Pomares, L., Gordon, S., and Wong, S. Y. The β-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol., 169: 3876-3882, 2002.